2025 ASCO前瞻｜一文速览47项乳腺癌Oral/Rapid Oral最新研究方向

2025年美国临床肿瘤学会（ASCO）年会即将于5月30日至6月3日在美国芝加哥正式召开。本次ASCO年会口头报告/快速口头报告（Oral/Rapid Oral）会场乳腺癌领域共计47项最新研究，涵盖遗传风险预防、围术期策略优化、新型疗法探索、支持治疗与技术创新，持续推动乳腺癌诊疗迈向精准分层、跨界联合、全程优化新阶段。中国学者领衔6项研究，在围术期策略优化、ADC药物、脑转移治疗等领域实现突破。【ONCO前沿】特此整理Oral/Rapid Oral会场乳腺癌领域最新研究标题等相关信息，以飨读者！

中文标题：neoCARHP研究：紫杉类药物+曲妥珠单抗+帕妥珠单抗±卡铂降阶新辅助治疗HER2+早期乳腺癌的多中心、开放标签、随机III期试验.

英文标题：De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial.

讲者：王坤教授 | 广东省人民医院

中文标题：基于临床病理变量与HER2DX基因组检测预测紫杉类药物+曲妥珠单抗+百帕妥珠单抗 (THP) 治疗II/III期HER2+乳腺癌的病理完全缓解 (pCR)率： EA1181/CompassHER2 pCR研究的次要结果。

英文标题：Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.

讲者：Nadine M. Tung, MD, FASCO | Beth Israel Deaconess Medical Center

中文标题：HER2+早期乳腺癌降级新辅助治疗后的生存预测： 三项WSG试验的汇总分析。

英文标题：Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials.

讲者：Monika Karla Graeser, MD | West German Study Group and Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany and Department of Gynecology, University Medical Center Hamburg

中文标题：2596例接受新辅助化疗的淋巴结阳性乳腺癌患者目标淋巴结标记技术对比：前瞻性、多中心 AXSANA/EUBREAST-03/AGO-B-053研究（NCT04373655）的结果。

英文标题：Comparison of marking techniques for target lymph nodes in 2,596 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study (NCT04373655).

讲者：Maggie Banys-Paluchowski, PhD | Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Lübeck

中文标题：ctDNA预测新辅助化疗后淋巴结负荷以指导手术规划：I-SPY2研究结果。

英文标题：Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.

讲者：Rita Mukhtar, MD | Division of Surgical Oncology, Department of Surgery, University of California, San Francisco

中文标题：SOFT /TEXT研究：依西美坦+卵巢功能抑制剂 (OFS) vs. 他莫昔芬+OFS辅助治疗绝经前HR+早期乳腺癌的15年生存结果

英文标题：15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.

讲者：Prudence A. Francis, MD, FRACP | Peter MacCallum Cancer Centre

中文标题：ASTRRA研究：绝经前HR+乳腺癌患者卵巢功能抑制治疗的最新生存结果和获益预测因素。

英文标题：Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor–positive breast cancer: Results from the ASTRRA trial.

讲者：Jai Min Ryu, MD, PhD | Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine

中文标题：辅助内分泌治疗+卵巢功能抑制对年轻胚系BRCA突变乳腺癌患者生存结果的影响：一项国际队列研究的二次分析。

英文标题：The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study.

讲者：Paola Zagami, MD | UNC Lineberger Comprehensive Cancer Center/University of Milan/ European institute of Oncology IRCSS (IEO)

中文标题：Elinzanetant用于辅助内分泌治疗相关血管舒缩症状的疗效和安全性：III期OASIS 4研究

英文标题：Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial.

讲者：Fatima Cardoso, MD | ABC Global Alliance

中文标题：ctDNA在接受新辅助内分泌治疗2/3期HR+/HER2-乳腺癌患者中的应用：I-SPY2 EOP研究。

英文标题：Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.

讲者：Silver Alkhafaji, BS | University of California, San Francisco

中文标题：III期NRG-BR003研究：多柔比星+环磷酰胺序贯每周紫杉醇±卡铂用于淋巴结阳性或高危淋巴结阴性TNBC的疗效对比。

英文标题：NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.

讲者：Vicente Valero, MD | The University of Texas MD Anderson Cancer Center

中文标题：奥拉帕利/卡铂（OC）vs. 多西他赛/表柔比星/环磷酰胺（TAC）新辅助治疗HRD早期TNBC的疗效和安全性：前瞻性随机II期试验ABCSG 45研究的主要结果。

英文标题：Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.

讲者：Christian F. Singer, MD, MPH | Department of Obstetrics and Gynecology and Center for Breast Health, Comprehensive Cancer Center, Medical University of Vienna and Austrian Breast and Colorectal Cancer Study Group

中文标题：NeoSTAR研究：应答指导下戈沙妥珠单抗+帕博利珠单抗（SG/P）新辅助治疗早期TNBC的II期试验

英文标题：A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.

讲者：Rachel Occhiogrosso Abelman, MD | Massachusetts General Hospital Cancer Center, Harvard Medical School

中文标题：Promise研究：CE/BZA vs. 安慰剂用于绝经后导管原位癌患者的术前随机临床试验

英文标题：The Promise study: A presurgical randomized clinical trial of CE/BZA vs placebo in postmenopausal women with ductal carcinoma in situ.

讲者：Swati Kulkarni, MD | Northwestern University Feinberg School of Medicine

中文标题：WinPro研究：内分泌治疗±孕酮用于绝经后HR+早期乳腺癌患者的机会窗口研究。

英文标题：The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer.

讲者：Lucy Haggstrom, MD | St Vincent's Hospital Sydney and University of New South Wales